___

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-1342. [CrossRef]

2. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160:293-300. [CrossRef]

3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567. [CrossRef]

4. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390:1345-1422. [CrossRef]

5. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571-583. [CrossRef]

6. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res 2014; 104:62-72. [CrossRef]

7. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J 2013; 10:1-11. [CrossRef]

8. Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol 2016; 65:1094-1103. [CrossRef]

9. Ingiliz P, Martin TC, Rodger A, Stellbrink H-J, Mauss S, Boesecke C, Mandorfer M, Bottero J, Baumgarten A, Bhagani S, Lacombe K, Nelson M, Rockstroh JK, NEAT study group. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 2017; 66:282-287. [CrossRef]

10. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016; 388:1081-1088. [CrossRef]

11. World Health Organisation. Combating hepatitis B and C to reach elimination by 2030 http://www.who.int/hepatitis/ publications/hep-elimination-by-2030-brief/en/ Erişim tarihi: 15 Ekim 2017. 12. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 2012; 107:1984-1995. [CrossRef]

13. Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs. Curr Opin Infect Dis 2015; 28:576-582. [CrossRef] 14. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62:932-954. [CrossRef]

15. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A Sustained virologic response reduces risk of allcause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-516. [CrossRef]

16. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015; 61:1860-1869. [CrossRef]

17. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56:1651-1660. [CrossRef]

18. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58:1598-1609. [CrossRef]

19. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66:153-194. [CrossRef]

20. Imperial College Applied Modelling Group. Global investment case document. London, 2016.

21. General Directorate of Health Research Turkey. Health Statistics Yearbook 2014 [Internet]. Ankara, 2014 [cited 2017 Oct 15] Available from: https://sbu.saglik.gov.tr/Ekutuphane/kitaplar/ EN YILLIK.pdf. (Turkish)

22. The Turkish Monitoring Center for Drugs and Drug Addiction (TUBIM). 2014 National Report (2013 Data) To the European Monitoring Center For Drugs and Drug Addiction by the REITOX National Focal Point (Turkey) - New Development, Trends and In-Depth Information on Selected Issues [Internet]. Ankara, 2014 [cited 2017 Oct 15] Available from: http:// www.emcdda.europa.eu/system/files/publications/1012/2014 TURKISH DRUG REPORT.pdf. (Turkish)

23. Ucbilek E, Abayli B, Koyuncu MB, Midikli D, Gozukucuk S, Akdag A, Ozdogan O, Altintas E, Sezgin O. Distribution of hepatitis C virus genotypes among intravenous drug users in the Çukurova region of Turkey. Turkish J Med Sci 2016; 46:66-71. [CrossRef]

24. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2014: Trends and developments. http://www.emcdda.europa.eu/publications/ edr/trends-developments/2014_en Available from: 15 Ekim 2017.

25. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013; 368:1859- 1861. [CrossRef]

26. Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy BioMed Central 2016; 1:1-10. [CrossRef]

27. Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, Jacobson LP, Detels R, Thio CL. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013; 57:77-84. [CrossRef]

28. Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J 2014; 11:1-8. [CrossRef]

29. Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013; 62:362- 365.

30. Alter MJ, Kuhnert WL, Finelli L, Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52:1-13. 31. Pawlotsky J-M. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36:65-73.

32. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of Hepatitis C infection. Hepatology 1998; 28:805-809. [CrossRef]

33. Schwarzinger M, Baillot S, Yazdanpanah Y, Rehm J, Mallet V. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: a nationwide retrospective cohort study. J Hepatol 2017; 67:454-461. [CrossRef]

34. Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol Alcohol 35:286-295. [CrossRef]

35. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004; 39:826-834. [CrossRef]

36. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, Boscarino JA, Henkle EM, Nerenz DR, Denniston MM, Holmberg SD, Chronic Hepatitis Cohort Study Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012; 55:1047-1055. [CrossRef]

37. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci 2007; 52:1168-1176. [CrossRef]

38. Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence 2012; 6:285-295. [CrossRef]

39. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Piratvisuth T, Marcellin P, Fried MW. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013; 57:1325-1332. [CrossRef]

40. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med Springer 2005; 20:754-758. [CrossRef]

41. Ho SB, Bräu N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, Marcus SG, Wasil MM, Tisi A, Huynh L, Robinson SK, Gifford AL, Asch SM, Groessl EJ. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol 2015; 13:2005-2014. [CrossRef]

42. Islam MM, Topp L, Conigrave KM, White A, Reid SE, Grummett S, Haber PS, Day CA. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. J Subst Abus Treat 2012; 43:440-445. [CrossRef]

43. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013; 57:56-61. [CrossRef]

44. Miller L, Fluker S-A, Osborn M, Liu X, Strawder A. Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc 2012; 104:244-250. [CrossRef]

45. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57:80-89. [CrossRef]

46. Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS One 2017; 12:e0178398. [CrossRef]

47. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374. [CrossRef]

48. Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012; 196:638-641. [CrossRef]

49. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ, Goldberg DJ, Martin TCS, Ramsay M, Hickman M, Hickman M. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016; 65:17-25. [CrossRef]